Metavia Inc (MTVA)

Apr 30, 2026

MSN Money - MSN

Apr 30, 2026

Apr 29, 2026

MetaVia (MTVA) price target decreased by 71.04% to 19.72 - MSN

Apr 29, 2026

Apr 29, 2026

MTVA Stock Price, Quote & Chart | METAVIA INC (NASDAQ:MTVA) - ChartMill

Apr 29, 2026

Apr 27, 2026

MetaVia (NASDAQ: MTVA) seeks votes on directors, reverse split authority and equity plan at 2026 meeting - Stock Titan

Apr 27, 2026

Apr 27, 2026

[ARS] MetaVia Inc. SEC Filing - Stock Titan

Apr 27, 2026

Apr 23, 2026

MetaVia (MTVA) price target decreased by 22.49% to 123.93 - MSN

Apr 23, 2026

Apr 20, 2026

MetaVia (MTVA) Stock Asset Based Valuation (Smart Money Exits) 2026-04-20Crowd Entry Points - Cổng thông tin điện tử Tỉnh Sơn La

Apr 20, 2026

Apr 15, 2026

MetaVia (MTVA) seeks shareholder approval for reverse split, equity plan at June 8 meeting - Stock Titan

Apr 15, 2026

Apr 13, 2026

Investment Recap: What is the next catalyst for MetaVia IncInsider Buying & Risk Managed Investment Strategies - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Performance Recap: Is MetaVia Inc a cyclical or defensive stockDay Trade & Free Growth Oriented Trading Recommendations - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Are executives confident in MetaVia (MTVA) Stock | MTVA Q4 Earnings: Beats Estimates by $0.85Management Guidance - Newser

Apr 13, 2026

Apr 10, 2026

MetaVia begins higher-dose trial of obesity drug DA-1726 By Investing.com - Investing.com Australia

Apr 10, 2026

Apr 10, 2026

MetaVia (MTVA) Begins Patient Dosing in Phase 1 Clinical Trial - GuruFocus

Apr 10, 2026

Apr 10, 2026

MetaVia Doses First Patient in Higher-Dose Phase 1 Trial of Dual GLP-1/Glucagon Agonist DA-1726 for Obesity Treatment 1 - Minichart

Apr 10, 2026

Apr 10, 2026

MetaVia Advances DA-1726 Obesity Trial With First Patient - TipRanks

Apr 10, 2026

Apr 10, 2026

MetaVia, LifeMD, Nike - TradingView

Apr 10, 2026

Apr 10, 2026

MetaVia begins higher-dose trial of obesity drug DA-1726 - Investing.com

Apr 10, 2026

Apr 10, 2026

MetaVia doses first patient in higher‑dose Phase 1 DA-1726 study; data due Q4 2026 - TradingView — Track All Markets

Apr 10, 2026

Apr 10, 2026

MetaVia (Nasdaq: MTVA) doses first patient in higher-dose DA-1726 obesity trial - Stock Titan

Apr 10, 2026

Apr 10, 2026

MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity - PR Newswire

Apr 10, 2026

Apr 10, 2026

Weekly Trades: Is MetaVia Inc in a consolidation phaseLayoff News & High Return Stock Watch Alerts - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

MetaVia Inc. (MTVA) Stock Forecast & Price Prediction 2026–2030 - CoinCodex

Apr 09, 2026

Apr 09, 2026

Update Recap: Is MetaVia Inc currently under institutional pressureMarket Trend Report & Community Consensus Picks - baoquankhu1.vn

Apr 09, 2026

Apr 07, 2026

MetaVia (NASDAQ: MTVA) registers resale of 936,846 shares - Stock Titan

Apr 07, 2026

Apr 07, 2026

[EFFECT] MetaVia Inc. SEC Filing - Stock Titan

Apr 07, 2026

Apr 07, 2026

MTVA Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 07, 2026

Apr 07, 2026

Is MetaVia (MTVA) Stock Good for Active Traders | Price at $1.21, Down 0.82%Crowd Sentiment Stocks - Newser

Apr 07, 2026

Apr 06, 2026

Market Recap: Can MetaVia Inc continue delivering strong returns2026 Geopolitical Influence & Free Community Consensus Stock Picks - baoquankhu1.vn

Apr 06, 2026

Apr 06, 2026

Will MetaVia (MTVA) Stock Rise in 2026 | Price at $1.25, Down 0.79%Expert Breakout Alerts - Newser

Apr 06, 2026

Apr 05, 2026

Entry Recap: Can MetaVia Inc continue delivering strong returnsPortfolio Update Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn

Apr 05, 2026

Apr 03, 2026

[POS AM] MetaVia Inc. SEC Filing - Stock Titan

Apr 03, 2026

Apr 02, 2026

MTVA Stock Analysis: MetaVia Inc. at 1.25 dollars with 4.17 percent session gain - Newser

Apr 02, 2026

Apr 01, 2026

1,896,385 Common Stock of MetaVia Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2026. - marketscreener.com

Apr 01, 2026

Apr 01, 2026

29,514 Restricted Stock Units of MetaVia Inc. are subject to a Lock-Up Agreement Ending on 2-APR-2026. - marketscreener.com

Apr 01, 2026

Apr 01, 2026

Maxim Group Maintains MetaVia(MTVA.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Apr 01, 2026

Apr 01, 2026

Market Trends: Can MetaVia Inc continue delivering strong returnsMarket Risk Analysis & Smart Swing Trading Alerts - baoquankhu1.vn

Apr 01, 2026

Apr 01, 2026

MTVA PE Ratio & Valuation, Is MTVA Overvalued - Intellectia AI

Apr 01, 2026

Mar 31, 2026

MTVA: Phase 1 Part 3 16-Week Titration Study of DA-1726 to Initiate in April 2026… - scr.zacks.com

Mar 31, 2026

Mar 30, 2026

Portfolio Shifts: Can MetaVia Inc stock outperform in a bear market2026 Market Outlook & Weekly Breakout Watchlists - baoquankhu1.vn

Mar 30, 2026

Mar 30, 2026

MetaVia stock price target lowered to $20 by H.C. Wainwright - Investing.com UK

Mar 30, 2026

Mar 29, 2026

Bearish Setup: Is now the right time to enter MetaVia IncMarket Movers & Fast Gaining Stock Reports - baoquankhu1.vn

Mar 29, 2026

Mar 29, 2026

Buy Signal: Is now the right time to enter MetaVia IncQuarterly Trade Report & Fast Momentum Stock Entry Tips - baoquankhu1.vn

Mar 29, 2026

Mar 28, 2026

Can MetaVia Inc stock outperform in a bear marketWeekly Gains Summary & Smart Swing Trading Alerts - baoquankhu1.vn

Mar 28, 2026

Mar 27, 2026

H.C. Wainwright cuts MetaVia stock price target to $20 on dilution - Investing.com

Mar 27, 2026

Mar 27, 2026

H.C. Wainwright cuts MetaVia stock price target to $20 on dilution By Investing.com - Investing.com India

Mar 27, 2026

Mar 27, 2026

Big Picture: Does MetaVia Inc outperform in volatile markets2026 Sector Moves & Community Verified Watchlist Alerts - baoquankhu1.vn

Mar 27, 2026

Mar 27, 2026

MetaVia Inc 2025 Annual Report: Clinical Progress, Risk Factors, and Cardiometabolic Drug Pipeline Overview - Minichart

Mar 27, 2026

Mar 26, 2026

MetaVia Updates Investor Strategy for Obesity and MASH - TipRanks

Mar 26, 2026

Mar 26, 2026

MetaVia Reports Positive 2025 Financial Results and Advances DA-1726 & Vanoglipel Clinical Programs for Obesity and MASH - Minichart

Mar 26, 2026